Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 11,255 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Oxidative Phosphorylation Deficiencies, Electron Transport Chain Disorders, Mitochondrial, Mitochondrial Disorders, Leigh Disease
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 4 Weeks to 115 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Infections, Pneumonia, Immune System Diseases, STAT3 Transcription Factor, Job Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 120 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis
Interventions: Sitagliptin; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 13 Years to 20 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide, Phosphate Buffer Saline (PBS),; Drug
Lead sponsor: Shire; Industry
Eligibility: 10 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Leukocyte Adhesion Deficiency Syndrome
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: PF-08049820, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Uncontrolled Gout
Interventions: Pegloticase, Methotrexate (MTX); Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 12 more

Conditions: Sickle Red Blood Cell, Fetal Hemoglobin, Oxidative Stress
Interventions: Broccosprouts® (Brassica Protection Products LLC) homogenate; Dietary Supplement
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cystic Fibrosis
Interventions: RCT2100, Placebo, Ivacaftor; Drug · Other
Lead sponsor: ReCode Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 10 more

Conditions: Fuchs' Endothelial Dystrophy
Interventions: Amphotericin B; Drug
Lead sponsor: Cornea Research Foundation of America; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Wrinkle
Interventions: BTL-785-7; Device
Lead sponsor: BTL Industries Ltd.; Industry
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Preterm Labor, Preterm Birth
Interventions: Multimodal intervention strategy; Other
Lead sponsor: Sera Prognostics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 6,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 18
States / cities: San Diego, California • New Haven, Connecticut • Newark, Delaware + 15 more

Conditions: Tourette Syndrome
Interventions: Sham Repetitive Transcranial Magnetic Stimulation, Active Repetitive Transcranial Magnetic Stimulation; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections
Interventions: Delavirdine mesylate; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 1 Month to 15 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Peapack, New Jersey

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: AC176; Drug
Lead sponsor: Accutar Biotechnology Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 2 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 21 Years to 35 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pompe Disease
Interventions: Pyridostigmine Bromide; Drug
Lead sponsor: University of Florida; Other
Eligibility: 8 Years to 60 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: cytarabine, omacetaxine mepesuccinate, decitabine, laboratory biomarker analysis; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 65 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Respiratory Distress Syndrome
Interventions: Lucinactant for inhalation, nCPAP alone; Combination Product · Device
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 26 Weeks to 28 Weeks
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Loma Linda, California • San Diego, California • Newark, Delaware + 7 more

Conditions: Behçet's Syndrome
Interventions: Apremilast, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 11
States / cities: Phoenix, Arizona • Sacramento, California • Ormond Beach, Florida + 8 more

Conditions: Psuedomas Infection, Cystic Fibrosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 9 Years to 80 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2018
U.S. locations: 4
States / cities: Bethesda, Maryland • Seattle, Washington • Madison, Wisconsin + 1 more

Conditions: Hemochromatosis
Interventions: Phlebotomy; Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinitis Pigmentosa
Interventions: Electro-acupuncture, Laser Acupuncture, Transcorneal Electrical Stimulation, Sham Electro-acupuncture, Sham laser acupuncture, Sham transcorneal electrical stimulation; Device
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Hemophilia A
Interventions: Desmopressin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Search by objective public record fields.

The NIH MINI Study: Metabolism, Infection, and Immunity in Inborn Errors of Metabolism

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

Gene Therapy for Patients With Leukocyte Adherence Deficiency (Follow-Up of Phase 1 Trial)

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

Effect of Broccoli Sprouts Homogenate on SS RBC

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.

BTL-785F Device for Improving the Structure of Facial Muscles

Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs

Repetitive Transcranial Magnetic Stimulation to Reduce Tics

A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Disclosing a Cystic Fibrosis Diagnosis to a Dating Partner

A Pilot Study of Pyridostigmine in Pompe Disease

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

The Role of Bacteria and Genetic Variations in Cystic Fibrosis

Treatment of Hemochromatosis

Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers